News | Cardio-oncology | September 28, 2016

Cardiac Risk a Factor When Considering Hormonal Therapy for Prostate Cancer

Decision analysis model study shows men with low-risk prostate cancer and history of heart attack may be harmed by adding hormone therapy to radiation therapy

prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016

September 28, 2016 — In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented at the American Society for Radiation Oncology (ASTRO) meeting, Sept. 25-28 in Boston.

Hormone therapy is used for treatment of prostate cancer to block the production of androgens, or male sex hormones. Androgens are necessary for the growth and spread of prostate cancer cells. Hormone therapy suppresses the androgen production in the body and stops the spread and growth of prostate cancer cells.

This study used a previously published decision analysis model that compared quality-adjusted life years (QALYs) in men aged 50, 60 and 70 years who received radiation therapy and no hormone therapy for high-risk prostate cancer and their cardiac risk factors. The research team used data from the recently published EORTC 22991 trial to study men with intermediate-risk prostate cancer, randomized to either radiation therapy or radiation therapy and six months of hormone therapy.

Hormone therapy was associated with a net decrease of 0.3 – 0.4 QALYs in men with a prior history of heart attack. However, for all other men, hormone therapy improved QALYs (range 0.4 - 2.6). Younger men with fewer cardiac risk factors experienced the largest benefit from hormone therapy. Men at low risk for biochemical failure (≤8.7 percent at 5 years) did not benefit from hormone therapy. Further, the benefits of hormone therapy did not begin to manifest until after 7.3 years of follow-up.

“Patient age, cardiac risk, and disease recurrence risk should be considered when selecting candidates for hormone therapy in this patient population,” said Nataniel Lester-Coll, M.D., first author on the study and a resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Men with a history of heart attack who are at very low risk for biochemical failure may be harmed by the addition of hormone therapy.”

For more information: www.astro.org

Related Content

Cell phone emissions cause cardiac tumors in males rats.
News | Cardio-oncology | February 06, 2018
High exposure to radiofrequency radiation (RFR) in rodents resulted in tumors in tissues surrounding nerves in the...
Videos | Cardio-oncology | February 01, 2018
American Heart Association (AHA) released a scientific statement Feb.
Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center for a cardio-oncology cancer patient to look for heart damage caused by chemotherapy or radiation therapy.

Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center. She is calling for more research and collaboration to examine the link between heart disease and breast cancer to develop new treatments and preventative measures.

Feature | Cardio-oncology | February 01, 2018
February 1, 2018 – Heart disease and breast cancer are two of the most prevalent diseases among women in the United S
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology | September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Pediatric echo protocols for cardio-oncology cardiotoxicity exams.
News | Cardio-oncology | June 15, 2017
 June 15, 2017 – Children who have suffered from cancer may also have lasting side effects from the drugs used in the
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
News | Cardio-oncology | May 03, 2017
Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (...
Videos | Cardio-oncology | June 30, 2016
Interview with Federico Asch, M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health
GE Ultrasound, GE echo, strain, cardio-oncology

GE Healthcare's cardiac ultrasound strain assessment software helps quantify left ventricular wall motion to determine if there is damage to cardiac function due to cancer therapy.

Feature | Cardio-oncology | May 11, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat...
News | Cardio-oncology | May 06, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement...
Overlay Init